Furthermore, results from phase III trials of oblimerson (Genasense), an antisense nucleotide that targets Bcl-2, in chronic lymphocytic leukaemia showed improved survival rates only when given in conjunction with conventional chemotherapy but not when used alone (O’Brien et al, 2007). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.